us too affected logo    

      News You Can Use

Us TOO Homepage | Donate | View Message in Your Browser | Change Email Preferences | Forward to a Friend


We invite you to read the most recent distribution of News You Can Use, which includes the prostate cancer articles listed below.  

On October 1, Us TOO joined representatives from other prostate cancer organizations to participate in a conference call hosted by Bayer HealthCare to proactively inform the prostate cancer community about the temporary supply disruption of Xofigo® (radium Ra 223 dichloride). Xofigo was recently approved by the FDA as treatment for men with castrate resistant metastatic prostate cancer (CRPC) with bone metastases without any known visceral metastases. Production delays are not uncommon with radiopharmaceuticals. Xofigo received by anyone to date is safe and meets all quality standards. This is a fluid situation and we will continue to monitor it.

Headlines of the News You Can Use articles are as follows and the full text is available at:

Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

New non-invasive technique could revolutionize the imaging of metastatic cancer

Blood test could identify when cancer treatment has become detrimental

Pitt study uncovers prostate cancer mystery

Findings from University of Michigan Provides New Data on Prostate Cancer (Risk of Second Primary Tumors in Men Diagnosed With Prostate Cancer) (Risk...

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as...

Genetic testing can identify men at 6-fold increased risk of prostate cancer

Prostate Cancer Awareness Month - Stop Random Biopsies

Findings in Urology Reported from Veterans Affairs Medical Center (Multiple Repeat Prostate Biopsies and the Detection of Clinically Insignificant...

Investigators at Harvard School of Public Health Report New Data on Cancer Research (Gleason grade progression is uncommon)

NCI -MD Anderson researchers discover gene that might predict aggressive prostate cancer at diagnosis

Studies from Ohio State University Yield New Information about Clinical Trials and Studies [The Individualized Diet and Exercise Adherence Pilot...

Metamark Announces Portfolio Expansion To Include PROGENSA® PCA3 And ERG Tests For Assessing Prostate Cancer

Patent Issued for Male Urethral Prosthesis with Tensioning Member

The November issue of the HotSheet will be out in about two weeks! Watch for more News You Can Use in about one month.

My best to you,

Thomas Kirk
President & CEO
Us TOO International
Des Plaines, IL 60018
Office: 630-795-1002
Toll Free: 800-808-7866
Tom Kirk 14
Donate Now!

Circles of Love National Health Council GreatNonprofits.jpg
Us TOO International Facebook Us TOO International Twitter Us TOO International LinkedIn
  Us TOO International YouTube Us TOO International Inspire Community  

Us TOO International Prostate Cancer Education & Support Network 

2720 S. River Road, Suite 112, Des Plaines, IL 60018-4106
P: 630-795-1002  F: 630-795-1602   
PCa HelpLine: 1-800-80-Us TOO (808-7866)